DOC2B通过KLC1依赖机制改善小鼠骨骼肌胰岛素敏感性
研究探讨DOC2B在骨骼肌胰岛素敏感性中的直接作用及机制。2型糖尿病供体骨骼肌DOC2B RNA降55%、蛋白降40%;小鼠骨骼肌过表达DOC2B改善糖耐量(雌性AUC降25%)和外周胰岛素敏感性(雌/雄曲线下面积增20%/26%),并抵抗高脂饮食诱导的胰岛素抵抗;机制涉及胰岛素刺激DOC2B磷酸化及与KLC1互作。
要点
- 2型糖尿病患者骨骼肌DOC2B表达显著降低
- 骨骼肌过表达DOC2B改善糖耐量及外周胰岛素敏感性
- DOC2B通过Y301磷酸化依赖的KLC1互作促进GLUT4膜转位
核心结论
- DOC2B与KLC1协同调控胰岛素刺激的GLUT4质膜累积,从而调节胰岛素敏感性,可作为2型糖尿病肌肉靶点。
研究设计与样本
- 评估非糖尿病与2型糖尿病供体人骨骼肌DOC2B表达。
- 构建多西环素诱导骨骼肌特异性Doc2b过表达小鼠,分标准饮食和高脂饮食组评估体内胰岛素/糖耐量及GLUT4膜累积。
- 体外采用DOC2B过表达的L6-GLUT4-myc成肌细胞/肌管结合胰岛素抵抗模型,通过定点突变、共免疫沉淀和质谱鉴定机制。
主要发现
- 2型糖尿病供体骨骼肌DOC2B RNA减少55%、蛋白减少40%。
- 骨骼肌DOC2B富集小鼠糖耐量改善(雌性AUC降25%),外周胰岛素敏感性提高(雌/雄曲线下面积增20%/26%)。
- DOC2B富集保护小鼠抵抗高脂饮食诱导的外周胰岛素抵抗,尽管肥胖持续存在。
- L6成肌细胞中DOC2B富集可在致糖尿病刺激下维持胰岛素刺激的GLUT4质膜累积。
- 胰岛素刺激DOC2B磷酸化,增强其与KLC1互作;Y301突变阻断磷酸化及KLC1结合,削弱GLUT4膜累积。
临床怎么用
- DOC2B可作为骨骼肌胰岛素增敏的潜在药物靶点。
- 靶向DOC2B-KLC1轴可能预防/治疗2型糖尿病,但需进一步临床验证。
局限性
- 主要证据来自小鼠模型和体外细胞系,人体因果性未确立。
- DOC2B过表达对肥胖本身无改善,仅保护胰岛素抵抗。
- 机制细节(如其他磷酸化位点或互作蛋白)未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Skeletal muscle accounts for >80% of insulin-stimulated glucose uptake; dysfunction of this process underlies insulin resistance and type 2 diabetes. Insulin sensitivity is impaired in mice deficient in the double C2 domain β (DOC2B) protein, while whole-body overexpression of DOC2B enhances insulin sensitivity. Whether insulin sensitivity in the skeletal muscle is affected directly by DOC2B or is secondary to an effect on other tissues is unknown; the underlying molecular mechanisms also remain unclear. METHODS: Human skeletal muscle samples from non-diabetic or type 2 diabetic donors were evaluated for loss of DOC2B during diabetes development. For in vivo analysis, new doxycycline-inducible skeletal-muscle-specific Doc2b-overexpressing mice fed standard or high-fat diets were evaluated for insulin and glucose tolerance, and insulin-stimulated GLUT4 accumulation at the plasma membrane (PM). For in vitro analyses, a DOC2B-overexpressing L6-GLUT4-myc myoblast/myotube culture system was coupled with an insulin resistance paradigm. Biochemical and molecular biology methods such as site-directed mutagenesis, co-immunoprecipitation and mass spectrometry were used to identify the molecular mechanisms linking insulin stimulation to DOC2B. RESULTS: We identified loss of DOC2B (55% reduction in RNA and 40% reduction in protein) in the skeletal muscle of human donors with type 2 diabetes. Furthermore, inducible enrichment of DOC2B in skeletal muscle of transgenic mice enhanced whole-body glucose tolerance (AUC decreased by 25% for female mice) and peripheral insulin sensitivity (area over the curve increased by 20% and 26% for female and male mice, respectively) in vivo, underpinned by enhanced insulin-stimulated GLUT4 accumulation at the PM. Moreover, DOC2B enrichment in skeletal muscle protected mice from high-fat-diet-induced peripheral insulin resistance, despite the persistence of obesity. In L6-GLUT4-myc myoblasts, DOC2B enrichment was sufficient to preserve normal insulin-stimulated GLUT4 accumulation at the PM in cells exposed to diabetogenic stimuli. We further identified that DOC2B is phosphorylated on insulin stimulation, enhancing its interaction with a microtubule motor protein, kinesin light chain 1 (KLC1). Mutation of Y301 in DOC2B blocked the insulin-stimulated phosphorylation of DOC2B and interaction with KLC1, and it blunted the ability of DOC2B to enhance insulin-stimulated GLUT4 accumulation at the PM. CONCLUSIONS/INTERPRETATION: These results suggest that DOC2B collaborates with KLC1 to regulate insulin-stimulated GLUT4 accumulation at the PM and regulates insulin sensitivity. Our observation provides a basis for pursuing DOC2B as a novel drug target in the muscle to prevent/treat type 2 diabetes.
引用
- Zhang J, Oh E, Merz KE, et al. DOC2B promotes insulin sensitivity in mice via a novel KLC1-dependent mechanism in skeletal muscle. Diabetologia. 2019. PMID: 30707251. doi:10.1007/s00125-019-4824-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。